For what reason might a newborn infant with a cardiac defect, such as coarctation of the aorta, receive prostaglandin E?

A. To decrease inflammation: While some prostaglandins (like those inhibited by NSAIDs) are involved in inflammation, Prostaglandin E1 (PGE_1) is used in neonates specifically for its effects on vascular smooth muscle. B. To control pain: Prostaglandin E does not have analgesic properties and is not used for pain management in neonates with heart defects. C. To decrease respirations: Prostaglandin E does not act as a respiratory depressant; it does not directly influence respiratory rate. D. To improve oxygenation: In conditions like coarctation of the aorta or ductus-dependent congenital heart defects, prostaglandin E1 maintains patency of the ductus arteriosus. This allows continued blood flow between the pulmonary artery and aorta, improving systemic perfusion and oxygen delivery to vital organs until surgical correction can be performed.